Omicron spread: Pfizer seeks conditional EU authorisation for Covid-19 pill

2 weeks ago 28

The European drug regulator said Monday it has started evaluating an application by Pfizer for its pill to treat the effects of COVID-19.

The announcement comes as countries in much of the 27-nation bloc are reporting soaring numbers of infections as the highly transmissible omicron variant sweeps across the continent.

The European Medicines Agency said in a statement that it could decide within weeks whether to approve Pfizer's application for a conditional marketing authorisation for the drug Paxlovid, depending on whether the data submitted are sufficiently robust and whether further information is required to support the evaluation.

Late last month, U.S. health regulators authorised the pill that patients will be able to take at home to ward off the worst effects of the virus. At the time, Pfizer said it had 180,000 treatment courses available worldwide, with roughly 60,000 to 70,000 allocated to the U.S. The company said it expected to have 250,000 available in the U.S. by the end of January.

Pfizer's application to the EMA covers use of the pill to treat mild to moderate COVID 19 in patients aged 12 years and older who are at risk of developing severe symptoms of the disease.

The EMA last month issued advice on use of the drug to EU nations that wanted to begin using it before official authorisation. The agency said it based its advice on a study of non-hospitalised, unvaccinated patients who had COVID-19 and at least one underlying condition that put them at risk of developing severe COVID-19 symptoms.

These data showed that Paxlovid reduced the risk of hospitalisation and death when treatment started within five days of the start of symptoms, the agency said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Read Entire Article